Pomegranate Health review

Pomegranate Health has a broader prescription menu than its weight-loss pages alone suggest. The public pricing app also lists NAD+, sermorelin, glutathione, B12 preparations and low-dose naltrexone. Its GLP-1 catalog needs closer attention. An earlier November 3 screen marked both compounded injections Sold Out with a BPI notice. A later screen displayed starting prices, several pharmacy options and no sold-out label. Those different public descriptions do not settle what a particular patient can obtain. The separate semaglutide and tirzepatide marketing pages also show starting prices and enrollment links. Obtain a current prescription-specific supply confirmation before treating any of those pages as an available offer.

The product descriptions also need to remain tied to the current proposal. The earlier app screen named tirzepatide with pyridoxine, a form of vitamin B6, and left the semaglutide additive unsettled. The later screen instead named tirzepatide with niacinamide B3 and semaglutide with cyanocobalamin B12. That difference matters when comparing preparations. Begin with the plan checklist and obtain the actual prescribed formulation, quantity and dispensing arrangement. Compounded medicines are not FDA-approved generic equivalents of branded products. The ingredient name alone cannot establish the quality, clinical suitability or results of the preparation a patient would receive.

Pomegranate's longevity options can be considered separately from its GLP-1 listings. NAD+ and sermorelin are presented as injections, with a one-month choice and a distinct three-month package total. The NAD+ guide and sermorelin guide provide background for discussing those preparations with a clinician. They do not prove the advertised energy, recovery or aging benefits of a particular prescription. A longer package also leaves practical questions about the quantity supplied, how shipments are spaced and what happens if treatment changes. Its lower average cost does not make it three separately refundable monthly purchases.

Glutathione, lipotropic B and C, methylcobalamin and cyanocobalamin appear as injectable options in the pricing app. Low-dose naltrexone is labeled a capsule. These should not be grouped into one interchangeable wellness treatment. In particular, cyanocobalamin has conflicting public price references: its product page and the app's one-month selection differ. The qualified table preserves both descriptions rather than selecting the cheaper one. The glutathione overview can help frame a conversation about evidence and preparation. A suggestion to add a product to an existing plan still needs a clinical reason, a defined supply and a separate explanation of the bill.

Pharmacy names on a selector answer only part of the dispensing question. Hallandale and TPH are visible options for several longevity products; the cyanocobalamin panel shows TPH in the observed choices. The earlier GLP-1 screen carried a BPI sold-out notice; the later screen offered several pharmacy choices. These labels do not confirm each facility's full legal identity, current license or assignment to a patient's prescription. Pomegranate's general terms also distinguish its technology platform from separate medical providers and pharmacies. Request the actual facility details for the proposed preparation and destination. A public choice on a product card is not confirmation that a pharmacy has accepted and can fill the prescription.

The main product pages use manufacturer and regulatory language alongside a disclaimer that compounded medicines have not been reviewed or approved by FDA. Keep those statements in their proper scopes. Registration or licensing claims about a facility are not FDA approval of the medicine, and a marketing illustration is not the actual prescription label. Pomegranate says its product images do not represent the dispensed vial, label or size. A patient therefore needs the real preparation and quantity confirmed through the clinical and pharmacy process. Neither an image nor a broad quality assurance statement supplies that information on its own.

The stated care process begins with an online intake and a virtual consultation with a licensed medical provider. A prescription follows only if the provider approves treatment, and ongoing medical support is described. The public material does not assign a particular clinician or settle whether every encounter uses live video. Pomegranate's platform address in Delaware is also not the address of a treating professional or dispensing facility. Clarify who provides clinical care, how follow-up is arranged and how to obtain records. Published contact hours describe support access; they should not be converted into a guarantee that a prescriber is continuously available or can handle an emergency.

Laboratory requirements are conditional. One FAQ says a provider may need results from within the preceding twelve months or other medical records. It does not establish that every patient needs the same tests or that any new testing is included in the advertised plan. The guide to program care fees helps separate a medication charge from professional and testing costs. Someone bringing existing records should establish whether they are sufficient before purchasing another test. That decision belongs with the treating professional, and a general reference to convenient online care does not settle the evaluation needed for an individual prescription.

Delivery estimates start after consultation and approval, with the FAQ describing three to five business days for most patients, depending on pharmacy processing and shipping. An estimate does not confirm the selected prescription is in stock. The public app also warns that Alaska, Puerto Rico and Hawaii may involve additional shipping charges and longer delivery. The later GLP-1 screen specifies a regional surcharge, separated in the price table; confirm its application to the selected order. Product pages describe included care, medication and shipping, so the selected destination and any exception should be reconciled before payment. Intended use within the United States and its territories does not establish current authorization for every product in every state.

No membership required is a useful marketing statement, but it does not mean there is no recurring payment. The subscription policy describes automatic renewal for the selected period until cancellation. It directs customers to contact support at least twenty-four hours before that period ends and also describes a profile-based cancellation sequence. Deleting an app is not cancellation. The billing comparison tool can keep the payment amount, term and renewal date together. Ending clinical visits or deciding not to use the remaining medication should not be assumed to stop the financial agreement; obtain confirmation of which renewal has actually been disabled.

Separate subscription cancellation from changing an appointment. The policy's late-cancellation fee refers to appointments canceled within twenty-four hours, rather than every request to stop a subscription. It also describes medication as nonrefundable and nonreturnable and says membership or one-time consultation fees, where applicable, are nonrefundable. Those references do not establish that a membership is mandatory for the currently advertised program. A prepaid package makes this distinction consequential: ending the next renewal may leave the current purchase intact. The policy also requires delivery or product problems to be reported within twenty-four hours, so the applicable reporting process should be understood before a shipment arrives.

The terms contain additional charges connected to certain payment disputes and a possible court proceeding. These are conditional clauses, not ordinary cancellation prices or a judgment about legal enforceability. Read the selected agreement rather than treating every fee mentioned in a general policy as inevitable. The privacy page likewise has a defined scope: its heading mentions HIPAA, but the body is a consumer-health-data notice referring to another general policy. Access, deletion, consent withdrawal and appeals have qualifications. Before sharing a medical history, clarify who holds the clinical record, which privacy notice applies and how to request it if the care relationship ends.

Pomegranate may be worth revisiting for a specifically defined longevity prescription, but the differing compounded GLP-1 catalog descriptions limit a comparison based on confirmed weight-care access. Its public plan choices provide useful reference points without establishing complete selected invoices. Pharmacy assignment, clinical arrangements, shipping exceptions and the differing cyanocobalamin prices still need resolution. Compare the Strut Health review and DirectMeds review using the same preparation, full-charge and exit questions. The decision should follow a clinician's prescription, confirmed supply and an understood agreement, rather than a starting figure or a broad wellness promise.